Ashley Varkey
YOU?
Author Swipe
View article: B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia Open
B cell maturation antigen (BCMA) has emerged as a prominent immunotherapeutic target in multiple myeloma (MM) due to its restricted expression on MM cells, plasma cells and mature B cells, with minimal presence in other normal tissues. In …
View article: Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager
Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager Open
Acute myeloid leukemia (AML) is a blood cancer which remains difficult to treat, especially in the setting of relapse or refractory status. Despite the success of immunotherapies such as CAR T and T cell engager therapies for the treatment…
View article: Ex Vivo Enriched Tumor Antigen-Specific T Cells Are Optimal Effectors of T Cell Engagers and Tumor-Specific T Cell Receptor/T Cell Engager Combination Provides Synergistic Efficacy Against Hematologic Malignancies
Ex Vivo Enriched Tumor Antigen-Specific T Cells Are Optimal Effectors of T Cell Engagers and Tumor-Specific T Cell Receptor/T Cell Engager Combination Provides Synergistic Efficacy Against Hematologic Malignancies Open
Multiple myeloma (MM) and acute myeloid leukemia (AML) are blood cancers that remain difficult to treat because a large proportion of patients have disease that does not respond to currently available therapies. NexImmune's Artificial Immu…